Zachary Canonico Portfolio
Invests via DIADEMA PARTNERS LP | Managed by Timothy Bassett, Zachary Canonico
Invests via DIADEMA PARTNERS LP
Managed by Timothy Bassett, Zachary Canonico
Automatically Tracked
Zachary Canonico Profile
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Investment Philosophy & Strategy
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
41.21%
Gain -0.62%
Monthly
1.71%
Yearly
22.61%
Drawdown
21.82%
$313.78M
Equity
Holdings
$313.78M
Investment
$294.3M
$60.3M
Profit -$1.74M
Realized
$40.83M
Unrealized
$19.47M
Dividends
$1.1M
Goals
Avg. 47% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-0.62%
Profit
-$1.74M
Win %
51%
This Week
Compared To Last Week
Gain
-3.48%
Profit
-$11.31M
Win %
51%
This Month
Compared to last month
Gain
-3.54%
Profit
-$11.52M
Win %
51%
This Year
Compared to last year
Gain
-1.11%
Profit
-$3.52M
Win %
57%
EQ Equillium, Inc.
+17.41%
+$140,098.7 
CUE Cue Biopharma, Inc.
+10.04%
+$150,911.28 
VERA Vera Therapeutics Inc.
+9.48%
+$157,845.92 
TVRD Cara Therapeutics Inc.
+7.34%
+$2,158.91 
MGTX MeiraGTx Holdings plc
+6.71%
+$7,112.8 
SPRB Spruce Biosciences Inc.
+5.77%
+$86,100 
CLRB Cellectar Biosciences, Inc.
+4.84%
+$16,600.92 
HELP Cybin Inc.
+4.72%
+$108,000 
FDMT 4D Molecular Therapeutics, Inc.
+4.63%
+$308,397.78 
RIGL Rigel Pharmaceuticals, Inc.
+4.39%
+$40,840.64 
PHAT Phathom Pharmaceuticals Inc.
+4.36%
+$51,980 
ARDX Ardelyx Inc.
+3.84%
+$45,453.75 
PRQR ProQR Therapeutics N.V.
+3.78%
+$64,821.12 
AYTU Aytu BioPharma Inc.
+3.48%
+$11,883.68 
MGNX Macrogenics Inc.
+3.43%
+$52,416.42 
KOD Kodiak Sciences Inc.
+3.43%
+$298,820.29 
XERS Xeris Biopharma Holdings, Inc.
+3.24%
+$35,841.42 
PHVS Pharvaris N.V.
+3.23%
+$32,253.07 
MNKD MannKind Corporation
+3.22%
+$1,920.36 
HRTX Heron Therapeutics Inc.
+3.03%
+$4,587.23 
ORKA Oruka Therapeutics, Inc.
+2.7%
+$81,173.11 
MNPR Monopar Therapeutics Inc.
+2.38%
+$4,286.9 
UPB Upstream Bio, Inc.
+2.31%
+$3,054.88 
EWTX Edgewise Therapeutics, Inc.
+2.29%
+$269,491.86 
RCUS Arcus Biosciences Inc.
+2.15%
+$138,762.2 
LRMR Larimar Therapeutics Inc.
+2.11%
+$13,197.33 
INDV Indivior Pharmaceuticals, Inc.
+2.07%
+$53,334.37 
UNCY Unicycive Therapeutics Inc.
+2.04%
+$33,404.36 
SYRE Spyre Therapeutics, Inc.
+1.75%
+$26,700 
COGT Cogent Biosciences, Inc.
+1.66%
+$306,071.68 
TLPH Talphera Inc.
+1.65%
+$3,071.26 
BIOA BioAge Labs, Inc.
+1.63%
+$24,876.78 
VYGR Voyager Therapeutics Inc.
+1.55%
+$20,682.1 
RNAC Cartesian Therapeutics Inc.
+1.38%
+$10,446.84 
APRE Clear Creek Independent School District
+1.34%
+$404.16 
ELVN Enliven Therapeutics, Inc.
+1.31%
+$7,599.99 
RLMD Relmada Therapeutics Inc.
+1.05%
+$18,068.35 
RVMD Revolution Medicines Inc.
+0.85%
+$238,064.17 
VKTX Viking Therapeutics Inc.
+0.76%
+$110,452 
ENTX Entera Bio Ltd.
+0.7%
+$465.2 
ANNX Annexon, Inc.
+0.57%
+$825.48 
VRDN Viridian Therapeutics Inc.
+0.41%
+$9,000 
CNTB Connect Biopharma Holdings Ltd.
+0.39%
+$1,969.85 
PEPG PepGen Inc.
+0.34%
+$3,732.84 
URGN Urogen Pharma Ltd.
+0.21%
+$713.7 
CRBP Corbus Pharmaceuticals Holdings, Inc.
+0.1%
+$3,012.64 
IMCR Immunocore Holdings plc American Depositary Receipt
+0.03%
+$2,548.63 
IVA Inventiva S.A.
0%
$0 
OCGN Ocugen Inc.
0%
$0 
JATT JATT II Acquisition Corp
0%
$0 1080
10806XAJ1
0%
$0 
SPRY Ars Pharmaceuticals Inc
-7.38%
-$2,187 
CTNM Contineum Therapeutics, Inc.
-7.25%
-$132,903.63 
PGEN Precigen Inc.
-6.01%
-$52,764.27 
PTHS Pelthos Therapeutics Inc.
-5.01%
-$35,920.85 
SMMT Summit Therapeutics Inc.
-4.64%
-$39,000 
FHTX Foghorn Therapeutics Inc.
-3.54%
-$15,388.84 
DFTX Definium Therapeutics, Inc.
-2.89%
-$19,622.77 
ZYME Zymeworks Inc.
-2.48%
-$90,964.48 
PRTA Prothena Corporation plc
-2.42%
-$32,886.04 
GLUE Monte Rosa Therapeutics, Inc.
-2.15%
-$26,652.94 
ABVX Abivax SA ADR
-2.05%
-$407,473.56 
BCYC Bicycle Therapeutics plc American Depositary Receipt
-2.01%
-$37,017.92 
NVO Novo Nordisk A/S Sponsored ADR
-1.78%
-$83,000 
MLYS Mineralys Therapeutics, Inc.
-1.73%
-$25,356.15 
BMRN Biomarin Pharmaceutical Inc.
-1.71%
-$366,029.82 
CRVS Corvus Pharmaceuticals Inc.
-1.65%
-$73,702.75 
PCVX Vaxcyte, Inc.
-1.34%
-$35,606.09 
HRMY Harmony Biosciences Holdings, Inc.
-0.99%
-$10,208.32 
NXTC NextCure, Inc.
-0.84%
-$541.94 
TSHA Taysha Gene Therapies Inc.
-0.67%
-$20,904.76 
JNJ Johnson & Johnson
-0.66%
-$38,059.49 
AMGN Amgen Inc.
-0.63%
-$270,104.66 
NRIX Nurix Therapeutics Inc.
-0.52%
-$17,015.58 
RLAY Relay Therapeutics Inc.
-0.35%
-$16,147.39 
UTHR United Therapeutics Corporation
-0.31%
-$81,602 
LAKE Lakeland Industries Inc.
-0.25%
-$423.24 
KLRA Kailera Therapeutics, Inc.
-0.17%
-$108.63 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 424 | Longs Won 212/424 50% | Profit Factor 2.27 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $812,348.4 |
| Average Win $509,180.82 | Best Trade (Aug 25) $8.39M | Sharpe Ratio -16.39 |
| Average Loss -$224,725.85 | Worst Trade (Dec 31) -$5.64M | Z-Score -0.53 (40.72%) |
| Commissions $0 | Avg. Trade Length 5m 1w 2d | Expectancy $142,227.48 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,397 | 1,257 | 1,117 | 978 | 838 | 698 | 559 | 419 | 279 | 140 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 1080 10806XAJ1 | 250,000 | $18.57M | $18.57M | - | - | - | 0.0 |
| ABVX Abivax SA ADR | 163,644 | $19.71M | $19.47M | - | -$241,654.25 | -1.23% | -2.05% |
| AMGN Amgen Inc. | 102,701 | $37.19M | $42.64M | - | $5.45M | 14.66% | -0.629% |
| ANNX Annexon, Inc. | 27,516 | $138,130.32 | $145,559.64 | - | $7,429.32 | 5.38% | +0.57% |
| APRE Clear Creek Independent School District | 44,907 | $36,029 | $30,536.76 | - | -$5,492.24 | -15.24% | +1.341% |
| ARDX Ardelyx Inc. | 303,025 | $1.55M | $1.23M | - | -$315,146.52 | -20.39% | +3.836% |
| AYTU Aytu BioPharma Inc. | 148,546 | $343,307.19 | $353,539.48 | - | $10,232.29 | 2.98% | +3.478% |
| BCYC Bicycle Therapeutics plc American Depositary Receipt | 462,724 | $2.15M | $1.8M | - | -$342,415.39 | -15.95% | -2.01% |
| BIOA BioAge Labs, Inc. | 146,334 | $2.91M | $1.55M | - | -$1.36M | -46.69% | +1.63% |
| BMRN Biomarin Pharmaceutical Inc. | 312,846 | $17.55M | $21.07M | - | $3.52M | 20.05% | -1.707% |
| CLRB Cellectar Biosciences, Inc. | 138,341 | $344,469.09 | $359,686.6 | - | $15,217.51 | 4.42% | +4.839% |
| CNTB Connect Biopharma Holdings Ltd. | 196,985 | $516,100.9 | $502,311.75 | - | -$13,789.15 | -2.67% | +0.394% |
| COGT Cogent Biosciences, Inc. | 493,664 | $15.76M | $18.72M | - | $2.97M | 18.83% | +1.662% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 301,264 | $2.83M | $3.04M | - | $210,884.95 | 7.45% | +0.099% |
| CRVS Corvus Pharmaceuticals Inc. | 294,811 | $4.33M | $4.39M | - | $61,150.85 | 1.41% | -1.651% |
| CTNM Contineum Therapeutics, Inc. | 119,733 | $1.96M | $1.7M | - | -$263,412.73 | -13.42% | -7.255% |
| CUE Cue Biopharma, Inc. | 48,369 | $1.24M | $1.65M | - | $418,875.54 | 33.91% | +10.039% |
| DFTX Definium Therapeutics, Inc. | 15,451 | $726,815 | $658,676.13 | - | -$68,138.87 | -9.37% | -2.893% |
| ELVN Enliven Therapeutics, Inc. | 10,000 | $504,670.25 | $588,200 | - | $83,529.75 | 16.55% | +1.309% |
| ENTX Entera Bio Ltd. | 23,260 | $25,819 | $67,221.4 | - | $41,402.4 | 160.36% | +0.697% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Zachary Canonico?
The largest contributions to the portfolio's profits come from the following stocks: Terns Pharmaceuticals, Inc - $15.79M, Jazz Pharmaceuticals plc - $3.79M, Regeneron Pharmaceuticals, Inc - $3.34M, INDV - $2.99M, and AbbVie Inc - $2.6M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Soleno Therapeutics, Inc - $5.32M, Teva Pharmaceutical Industries Ltd. ADR - $2.07M, Nektar Therapeutics Inc - $1.27M, Eli Lilly and Company - $1.14M, and Arcus Biosciences Inc - $1.04M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Zachary Canonico's portfolio generate?
The portfolio generates substantial dividend income, with a total of $1.1M earned over time. The largest contributors to dividend income include Amgen Inc - $382,804.52, Johnson & Johnson - $187,910.34, Bristol-Myers Squibb Company - $179,800, AbbVie Inc - $123,620.34, and Regeneron Pharmaceuticals, Inc - $67,405.6. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Zachary Canonico's monthly returns?
Zachary Canonico's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Zachary Canonico's strategy be considered aggressive or moderate?
Zachary Canonico's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Zachary Canonico's strategy?
Zachary Canonico's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
